Tags: Chimerix | Ebola Outbreak | Tekmira

Ebola Drugs Vie for Market Dominance

By
Tuesday, 28 Oct 2014 02:31 PM Current | Bio | Archive

An Ebola epidemic is terrifying, whether it is on the other side of the world or in New York. Still, until recently the rush for a treatment or a vaccine was a backburner pursuit and an almost non-story. Few companies seemed interested and almost no attention was paid to the few research projects being conducted.

Then, someone died of Ebola on American soil and the public freaked out.

This sort of reactionary public relations is common in the pharmaceutical industry because treatment and vaccine research is incredibly expensive. Before a company invests in a vaccine or other treatment for Ebola, it must be assured that its odds of recouping its investment are substantial.

The hard math may not be pleasant to hear, but it is the market reality. Now, with the sudden international attention being paid to Ebola, as well as the very real potential of an outbreak in America, companies are rushing to gain a market lead in treatments and a vaccine.

Three particular companies are outpacing all others in the pharmaceutical industry: Chimerix, Mapp Biopharmaceutical, and Tekmira are all hard at work developing both treatments and eventual vaccines for this disease.

Mapp and Tekmira each have an early lead in the race for an Ebola — both have been successful in developing treatments conducting monkey tests. Regardless of which company holds the current lead, most industry prognosticators are indicating that a successful treatment option could be released — at least on an emergency basis — early next year with a vaccine for Ebola expected roughly a year thereafter.

The race to be the first could not have higher stakes.

Not only will a successful Ebola treatment be seen as a miracle drug — the company that creates it will gain an unshakeable public relations foothold — as long as it works.

Ronn Torossian is one of America’s foremost Public Relations executives as founder/CEO of 5WPR, a leading independent PR Agency. The firm was honored as PR Firm of the Year by The American Business Awards, and has been named to the Inc. 500 List. Torossian is author of the best-selling "For Immediate Release: Shape Minds, Build Brands, and Deliver Results with Game-Changing Public Relations." For more of Ronn Torossian's reports, Go Here Now.

© 2017 Newsmax. All rights reserved.

 
1Like our page
2Share
RonnTorossian
Not only will a successful Ebola treatment be seen as a miracle drug — the company that creates it will gain an unshakeable public relations foothold — as long as it works.
Chimerix, Ebola Outbreak, Tekmira
370
2014-31-28
Tuesday, 28 Oct 2014 02:31 PM
Newsmax Inc.
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
America's News Page
© Newsmax Media, Inc.
All Rights Reserved